Patheon sells clinical packaging business to Bellwyck

Published: 7-Sep-2012
Packaging Regulatory

Part of strategic plan to focus on solid dose and parenteral development and manufacturing


Patheon has sold its global secondary clinical packaging and clinical distribution services business to Bellwyck Packaging Solutions, a private company with 20 years’ experience providing clinical trial and contract services for secondary packaging.

‘We are very happy to have reached an agreement with Bellwyck for this business,’ said James C. Mullen, Patheon's Chief Executive Officer. ‘This transaction is part of our continued focus on our core competencies of solid-dose and parenteral development and manufacturing.’

Patheon's secondary clinical packaging and clinical distribution services business is globally managed from its Burlington, Ontario, Canada facility, and includes an operating presence in Cincinnati, Ohio. Terms of the sale have not been disclosed.

  • Companies:
  • Patheon
  • Bellwyck Packaging Solutions
See more

You may also like

Manufacturing

PCI expands in Canada with clinical trial services acquisition

Read more
Bellwyck Pharma Services has joined US-based PCI’s global network

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. Gerresheimer acquires Bormioli Pharma Group through Blitz LuxCo Sarl merger Gerresheimer and Bormioli Pharma will merge to provide the biotech and pharmaceutical industries with primary packaging solutions, dosing systems, closure solutions and accessories
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

PCI expands in Canada with clinical trial services acquisition

Bellwyck Pharma Services has joined US-based PCI’s global network
Regulatory

Fortress Biotech subsidiary Caelum Biosciences enters biopharmaceutical manufacturing agreement with Patheon

Agreement will support Phase II/III studies of Caelum's CAEL-101 in AL amyloidosis
Regulatory

Patheon outsources most NDAs of any provider

Company held approximately 30% of all outsourced approvals in 2016, four times more than the nearest competitor
Containment

Patheon regulatory expert to present at 2014 PIC/S Annual Seminar

Presentation will showcase Patheon’s strategic plan for manufacturing selective cytostatic tablets at the Bourgoin multiproduct facility
Manufacturing

Patheon launches updated Quick to Clinic programme

Offers customers a 12-week clinical trial programme that delivers maximum speed, but does not compromise quality
Manufacturing

Patheon to expand drug facility in France

Patheon is expanding its manufacturing facility in France to enable it to bring to Europe the same services that it offers from its plants in North America
Packaging

Patheon extends sterile filling capabilities at Swindon

<p>Patheon, a global provider of drug development and manufacturing services to the pharmaceutical industry, has extended its aseptic vial filling capabilities at its Swindon, UK facility to include the commercial supply of small-scale specialist products. </p>
Subscribe now